News
Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...
Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...
1d
mlive on MSN‘Potential exposure’ at Portage Pfizer plant sends people to hospital, MIOSHA investigating
Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc., in collaboration with Merck Sharp & Dohme LLC, is conducting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results